TECENTRIQ + COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib)

Targeted Therapy Run-in Followed by Triplet Dosing With TECENTRIQ 1

Dosing information for COTELLIC and ZELBORAF is based on the IMspire150 trial; TECENTRIQ was administered q2w in IMspire150. Visualization of vials is illustrative and does not represent actual vial usage.
bid=twice a day; IV=intravenous; qd=every day; q2w=every 2 weeks.

TECENTRIQ can be administered in 30-minute infusions, if the initial 60-minute infusion is tolerated 1


  • Do not administer TECENTRIQ as an IV push or bolus
  • Do not co-administer other drugs through the same IV line
  • Refer to the Prescribing Information for COTELLIC and ZELBORAF for recommended dosing information 

Dosage modifications from the TECENTRIQ Prescribing Information 1

Adverse reaction Severity of adverse reaction* Dosage modifications
Pneumonitis  Grade 2 Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 3 or 4 Permanently discontinue
Hepatitis AST or ALT >3 and ≤8 times ULN or total bilirubin >1.5 and ≤3 times ULN
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
AST or ALT >8 times ULN or total bilirubin >3 times ULN
Permanently discontinue
Hepatitis (for patients with HCC)
 
  • AST or ALT is within normal limits at baseline and increases to more than 3 and up to 10 times the ULN
  • AST or ALT is more than 1 and up to 3 times the ULN at baseline and increases to more than 5 and up to 10 times the ULN
  • AST or ALT is more than 3 and up to 5 times the ULN at baseline and increases to more than 8 and up to 10 times the ULN
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
AST or ALT increases to more than 10 times the ULN or total bilirubin increases to more than 3 times the ULN
Permanently discontinue
Colitis or diarrhea Grade 2 or 3
Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4
Permanently discontinue
Endocrinopathies
Grade 2, 3, or 4
Withhold dose until grade 1 or resolved and clinically stable on hormone replacement therapy
Other immune-mediated adverse reactions involving a major organ Grade 3 Withhold dose until grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg per day (or equivalent)
Grade 4 Permanently discontinue
Infections Grade 3 or 4 Withhold dose until grade 1 or resolved
Infusion-related reactions Grade 1 or 2 Interrupt or slow the rate of infusion
Grade 3 or 4 Permanently discontinue
Persistent grade 2 or 3 adverse reaction (excluding endocrinopathies) Grade 2 or 3 adverse reaction that does not recover to grade 0 or 1 within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Inability to taper corticosteroid Inability to reduce to less than or equal to prednisone 10 mg per day (or equivalent) within 12 weeks after last TECENTRIQ dose
Permanently discontinue
Recurrent grade 3 or 4 adverse reactions Recurrent grade 3 or 4 (severe or life-threatening) adverse reactions
Permanently discontinue


ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.

*Graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0).

Including but not limited to hypophysitis, adrenal insufficiency, hyperthyroidism, and type 1 diabetes mellitus.

Refer to the Prescribing Information for COTELLIC and ZELBORAF for dosage modification information.